help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on August 14, 2007
Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2007-0322
A more recent version of this article appeared on November 1, 2007
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
92/11/4373    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nissen, P. H.
Right arrow Articles by Mosekilde, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nissen, P. H.
Right arrow Articles by Mosekilde, L.
Related Collections
Right arrow Calcium and Bone Metabolism

Submitted on February 12, 2007
Accepted on August 7, 2007

Molecular Genetic Analysis of the Calcium Sensing Receptor Gene in Patients Clinically Suspected to have Familial Hypocalciuric Hypercalcemia: Phenotypic Variation and Mutation Spectrum in a Danish Population

Peter H. Nissen*, Signe E. Christensen, Lene Heickendorff, Kim Brixen, and Leif Mosekilde

Department of Clinical Biochemistry and Department of Endocrinology and metabolism C, Aarhus University Hospital, Aarhus Sygehus, Denmark Department of Endocrinology, Odense University Hospital, Denmark

* To whom correspondence should be addressed. E-mail: sci08phn{at}as.aaa.dk.

Context: The autosomal dominantly inherited condition familial hypocalciuric hypercalcemia (FHH) is characterised by elevated plasma calcium levels, relative or absolute hypocalciuria, and normal to moderately elevated plasma PTH. The condition is difficult to distinguish clinically from primary hyperparathyroidism, and is caused by inactivating mutations in the calcium sensing receptor (CASR) gene.

Objective: We sought to define the mutation spectrum of the CASR gene in a Danish FHH population, and to establish genotype–phenotype relationships regarding the different mutations.

Design and participants: 213 subjects clinically suspected to have FHH, and 121 subjects enrolled as part of a family-screening program were studied. Genotype–phenotype relationships were established in 66 mutation positive index patients and family members.

Main outcome measures: We determined CASR gene mutations, and correlating levels of plasma calcium (albumin corrected), ionized calcium (pH 7.4) and PTH were measured.

Results: We identified 22 different mutations in 39 FHH families. We evaluated data on circulating calcium and PTH for 11 different mutations, representing a spectrum of clinical phenotypes, ranging from calcium concentrations moderately above the upper reference limit, to calcium levels more than 20% above the upper reference limit. Furthermore, the mean plasma PTH concentration was within the normal range in eight of 11 studied mutations, but mild to moderately elevated in families with the mutations p.C582Y, p.C582F and p.G553R.

Conclusions: The present data adds 19 novel mutations to the catalogue of inactivating CASR mutations and illustrates a variety of biochemical phenotypes in patients with the molecular genetic diagnosis FHH.


Key words: Familial hypocalciuric hypercalcemia • CASR • Calcium sensing receptor • mutation • phenotype







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2007 by The Endocrine Society